A phase I study on stereotactic body radiotherapy of liver metastases based on functional treatment planning using positron emission tomography with 2-[¹⁸F]fluoro-2-deoxy-d-galactose

Figures & data

Table 1. Patient characteristics.

#ID	Age	Gender	^aChemotherapy before/after SBRT	Liver segment	Number of metastases	Prior local therapy
1	72	M	No/no	VI	1	SBRT
2	86	F	No/no	VIII	1	SBRT and RFA
3	59	M	No/no	VII	1	SR
4	68	M	Yes/no	IV	1	SR, SBRT, RFA
5	67	F	No/yes	IV	1	SR, RFA
6	75	F	No/no	VII	1	SBRT and SR
7	73	M	No/yes	VII/VII	2	–
8	76	M	Yes/no	IV	1	–
9	76	F	No/no	IV/V	2	SBRT and RFA
10	56	M	Yes/yes	VII	1	–
11	72	M	Yes/yes	IV/VIII	2	–
12	71	F	No/yes	IV/VIII	2	–
13	80	M	No/no	IV and VIII	1	SR and RFA
14	66	F	No/yes	VIII	1	–

SBRT: stereotactic body radiotherapy; M: Male; F: Female; RFA: radiofrequency ablation; SR: surgical resection.

^a Chemotherapy administered the last three months before SBRT or the first three months after SBRT.

Figure 1. Dose-volume histogram (DVH) of V_Liver, V’_∼10%, V’_∼20% and V’_∼30% in patient #10 treated with FDGal PET/CT based FTP-SBRT with a total dose of 56.25 Gy in three fractions (A). The spatial distribution of FDGal (V’_∼10%, V’_∼20% and V’_∼30%) in the liver displayed together with the dose color wash of 15 Gy (B).

Table 2. Individual dose volume parameters.

#ID	Dose/fractions	^aBED (Gy)	∑CTV (cc)	∑PTV (cc)	VLiver (cc)	VLiver<15Gy (cc)	DLiver (Gy)	D’∼10% (Gy)	D’∼20% (Gy)	D’∼30% (Gy)	V’∼10% (cc)	V’∼20% (cc)	V’∼30% (cc)
1	60/6	44.1/3	11.6	40.0	1328	1239	^b3.7	^b5.5	^b7.4	^b5.1	38	94	237
2	56.25/3	–	12.2	48.9	1071	874	8.1	1.0	2.3	2.3	110	207	330
3	56.25/3	–	2.0	17.8	1526	1396	4.3	0.7	1.3	1.8	107	317	525
4	60/6	44.1/3	50.8	133.3	1532	1117	^b15.1	^b17.8	^b17.0	^b14.5	80	246	529
5	54/6	39.8/3	127.7	261.4	1833	1445	^b13.3	^b21.0	^b20.0	^b18.1	92	154	258
6	56.25/3	–	91.0	203.6	1667	1025	15.6	9.5	9.9	10.7	124	307	571
7	56.25/3	–	10.4	40.6	1262	1112	4.6	0.4	0.7	1.5	96	253	426
8	56.25/3	–	24.4	66.4	2291	1864	6.9	10.0	8.2	7.3	74	225	470
9	56.25/3	–	16.3	60.9	1779	1394	9.8	4.0	5.4	6.3	82	234	485
10	56.25/3	–	141.4	262.4	1796	1255	11.7	5.2	6.6	8.7	86	239	473
11	56.25/3	–	189.7	365.2	1529	818	18.4	11.3	12.6	13.5	110	283	496
12	45/3	–	167.0	342.8	1199	725	15.9	17.4	14.2	13.4	84	294	521
13	56.25/3	–	65.7	146.4	1439	1019	12.5	12.3	10.6	9.4	132	221	419
14	56.25/3	–	74.5	170.6	1965	1448	11.5	13.1	12.6	10.4	58	188	520

^a BED: Biologically effective dose (α/β = 3 for liver tissue).

^b Converted from six to three fractions.

Figure 2. Radiation dose-response relationship between hepatic metablic function (solid line) one month after FTP-SBRT delivered in three fractions as function of radiation dose with 95% confidence interval (dashed lines) and mean values in each dose interval (dots).